Based on the positive results of phase I/II trials on pembrolizumab for cervical cancer, the FDA approved pembrolizumab as a monotherapy in patients with recurrent or metastatic PD-L1 positive disease in 2018. This evidence concerns the gene CD274 and cervical carcinoma.